Journal article · 2023 · Open access

OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications

Christopher Stovin, Mark Russell, Edward Alveyn, Olukemi Adeyemi, Vishit Patel, Maryam A. Adas, Fabiola Atzeni, Kenrick K H Ng, Andrew I Rutherford, Sam Norton, Andrew P. Cope, James Benjamin Galloway

Rheumatology, 62(Supplement_2) · Published 1 April 2023 · DOI 10.1093/rheumatology/kead104.008

Open PDFView at the publisherCite this paper

In brief

“OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications” is a 2023 journal article by Christopher Stovin and 11 co-authors, published in Rheumatology. OpenAlex counts 2 citations as of 19 November 2026. It is open access: the full text is free to read at Rheumatology.

Citations
2
Most cited in
2023 (1)
Authors
12

Abstract

Background/Aims Concerns have been raised about the risk of malignancy with Janus kinase inhibitors (JAKi) following the ORAL Surveillance study, which reported an increased incidence of malignancy with tofacitinib compared with Tumor Necrosis Factor-α inhibitors (TNFi) in people with rheumatoid arthritis (RA) aged over 50 years who had additional cardiovascular risk factors. Our objective was to estimate the risk of malignancy for all licenced JAKi across disease indications, compared with TNFi, methotrexate (MTX), and placebo. Methods A systematic search of electronic databases (Medline, EMBASE, Cochrane) was performed to identify Phase 2/3/4 RCTs and long-term extension (LTE) studies of JAKi (tofacitinib, baricitinib, upadacitinib, filgotinib, peficitinib) in adults with RA, psoriatic arthritis, psoriasis, axial spondyloarthritis, inflammatory bowel disease, or atopic dermatitis. Comparators were placebo, MTX, and TNFi. Random-effects meta-analysis was performed to compare malignancy incidence rates between JAKi and comparators. Our primary outcome measure was the incidence of all malignancies including non-melanomatous skin cancers (NMSC). Secondary outcomes were malignancies excluding NMSC, and NMSC only. Results In 62 eligible RCTs and 14 LTE studies, there were 71,767 person-years of exposure to JAKi; 2,680 to placebo; 7,827 to TNFi; and 1,074 to MTX. Comparing JAKi with placebo arms of RCTs, the incidence rate ratio (RR) for all malignancies including NMSC was not significantly different (RR 0.81; 95% CI 0.52 to 1.26; p = 0.36). Similarly, when comparing JAKi with MTX, no significant differences were observed in the incidence of malignancy (RR 0.73; 95% CI 0.33 to 1.61; p = 0.43). Compared with TNFi, however, administration of JAKi was associated with an increased incidence of malignancy (RR 1.54; 95% CI 1.19 to 2.01; p = 0.001). For all analyses, findings were consistent when excluding NMSC, when analysing NMSC only, and when including LTE data. Conclusion In trial settings, JAKi do not associate with an increased risk of malignancy compared with placebo or MTX, but are associated with an increased risk of malignancy relative to TNFi. Disclosure C. Stovin: None. M.D. Russell: Honoraria; Lilly, Galapagos, Biogen, Menarini. Other; Lilly, Pfizer, Janssen, UCB. E. Alveyn: None. O. Adeyemi: None. V. Patel: None. M.A. Adas: None. F. Atzeni: None. K.K.H. Ng: None. A.I. Rutherford: None. S. Norton: None. A.P. Cope: Consultancies; BMS, Abbvie, GSK/Galvini. Grants/research support; BMS. J.B. Galloway: Honoraria; Abbvie, Biovitrum, BMS, Celgene, Chugai, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Sobi, UCB.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Stovin, C., Russell, M., Alveyn, E., Adeyemi, O., Patel, V., Adas, M. A., Atzeni, F., Ng, K. K. H., Rutherford, A. I., Norton, S., Cope, A. P., & Galloway, J. B. (2023). OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications. Rheumatology, 62(Supplement_2). https://doi.org/10.1093/rheumatology/kead104.008

MLA 9

Stovin, Christopher, et al. “OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications.” Rheumatology, vol. 62, no. Supplement_2, 2023. https://doi.org/10.1093/rheumatology/kead104.008.

Chicago

Stovin, Christopher, Mark Russell, Edward Alveyn, Olukemi Adeyemi, Vishit Patel, Maryam A. Adas, Fabiola Atzeni, et al. 2023. “OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications.” Rheumatology 62 (Supplement_2). https://doi.org/10.1093/rheumatology/kead104.008.

Harvard

Stovin, C. et al. (2023) ‘OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications’, Rheumatology, 62(Supplement_2). doi:10.1093/rheumatology/kead104.008.

IEEE

C. Stovin et al., “OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications,” Rheumatology, vol. 62, no. Supplement_2, 2023, doi: 10.1093/rheumatology/kead104.008.

BibTeX

@article{stovin2023inhibitors,
  title     = {{OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications}},
  author    = {Stovin, Christopher and Russell, Mark and Alveyn, Edward and Adeyemi, Olukemi and Patel, Vishit and Adas, Maryam A. and Atzeni, Fabiola and Ng, Kenrick K H and Rutherford, Andrew I and Norton, Sam and Cope, Andrew P. and Galloway, James Benjamin},
  journal   = {Rheumatology},
  year      = {2023},
  volume    = {62},
  number    = {Supplement_2},
  doi       = {10.1093/rheumatology/kead104.008},
  url       = {https://doi.org/10.1093/rheumatology/kead104.008}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • cancer risk
  • cancer incidence
  • tofacitinib
  • baricitinib
  • upadacitinib
  • filgotinib
  • peficitinib
  • tumor necrosis factor inhibitors

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Stovin, C., Russell, M., Alveyn, E., Adeyemi, O., Patel, V., Adas, M. A., Atzeni, F., Ng, K. K. H., Rutherford, A. I., Norton, S., Cope, A. P., & Galloway, J. B. (2023). OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications. Rheumatology, 62(Supplement_2). https://doi.org/10.1093/rheumatology/kead104.008

How many times has this paper been cited?

2 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Rheumatology: sign in and open the PDF from this page.

Who wrote this paper?

Christopher Stovin, Mark Russell, Edward Alveyn, Olukemi Adeyemi, Vishit Patel, Maryam A. Adas, Fabiola Atzeni, Kenrick K H Ng, Andrew I Rutherford, Sam Norton, Andrew P. Cope, James Benjamin Galloway.

What is the DOI of this paper?

10.1093/rheumatology/kead104.008, permanently at https://doi.org/10.1093/rheumatology/kead104.008. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.